Ana C. P. Correia

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Due to improved understanding of the role of bone morphogenetic protein 4 (BMP4) in an increasing number of diseases, the development of selective inhibitors of BMP4 is an attractive therapeutic option. The currently available BMP4 inhibitors are not suitable as therapeutics because of their low specificity and low effectiveness. Here, we compared newly(More)
  • 1